Florida just put taxpayer money behind testing cheap, old medicines—naming ivermectin—against cancer, and the stakes are huge.
Story Snapshot
- Florida funded a program that includes generic drug repurposing for cancer, citing ivermectin as an example.
- The state opened a $60 million funding round for 2025–26 research grants with awards up to $2 million.
- A published award list shows a Florida team funded to study ivermectin in a specific lung cancer subtype.
- The American Cancer Society says ivermectin is not an approved cancer treatment today.
Florida’s Bet: Push Faster, Cheaper Paths to Cancer Trials
Florida’s Department of Health launched a funding call that explicitly prioritizes research on repurposing generic drugs for cancer, listing ivermectin as an example. The call set aside about $60 million in the 2025–26 cycle, with up to $2 million per award, and tied funding to legislative appropriations. The state framed the move as part of a push to speed practical cancer research inside Florida’s institutions. The approach points money at ideas that could reach patients faster if they work.
The program sits within the Casey DeSantis Cancer Research Program and the Florida Cancer Connect Collaborative, which oversee how grants flow and how results translate to care models. The structure signals a focus on getting trials designed, data collected, and findings shared. State leaders amplified the push with announcements that highlighted new award cycles and the growing pool for applicants. One governor’s office release described the program’s rounds and its intent to support Florida labs and startups.
Direct Evidence: A Named Ivermectin Cancer Grant
A Florida award list for the 2025–26 period shows funding to the H. Lee Moffitt Cancer Center to study ivermectin for a form of non–small cell lung cancer defined by KEAP1 and NRF2 mutations. The document lists the investigator, institution, and the award amount, and it places the project in the generic drug repurposing category. That line item confirms the policy is not just talk. It is paying for a targeted study in a tough cancer subtype where options are limited.
Supporters argue generic medicines have known safety profiles, clear manufacturing paths, and low costs that can speed early steps. A systematic review of drug repurposing in oncology supports the logic but warns the pipeline is thin and uneven, with few robust randomized trials completed to date. That pattern suggests a sober view: preclinical promise and small uncontrolled reports often fail under rigorous testing. Florida’s design—fund more trials—aims to answer these questions with real data.
What This Means for Patients Today
Patients should understand what this funding is and what it is not. The American Cancer Society states that ivermectin is not approved to treat any cancer, and no clinical guidelines recommend it for cancer care today. That guidance holds while trials run. The point of Florida’s grants is to test ideas that might help, not to declare victories before results arrive. Good trials protect patients, find what works, and retire what does not. That is how medicine earns trust.
🚨 FLORIDA INVESTS $140 MILLION IN CANCER RESEARCH — A NEW CHAPTER FOR INNOVATION?
Florida’s Cancer Innovation Fund is drawing attention to research exploring new approaches to cancer prevention and treatment, including nutrition, metabolic health, exercise, and other emerging… pic.twitter.com/71FL1Mn5oU
— GENIX MEDS | BUY IVERMECTIN,MEBENDAZOLE AND MORE (@genixmeds) October 14, 2026
Florida’s move aligns with a common-sense view many conservatives share: spend public dollars where they can do the most good for the most people. If a low-cost medicine shows benefit, families and budgets win. If it fails, transparency and closure help patients avoid false hope and wasted money. The program’s emphasis on Florida-based teams also builds local capacity, anchors jobs, and keeps breakthroughs at home. That is prudent governance and smart healthcare strategy rolled into one.
How to Judge the Next Headlines
Watch for trial design, not just lab buzz. Randomized, controlled studies beat uncontrolled case series every time for deciding care. Look for clear endpoints, like survival or response rates, and plain reporting on side effects. Follow whether state-backed teams register trials, enroll on time, and publish on schedule. When results land, weigh them against standard treatments, not against wishful thinking. Policy won when it funded strong tests; patients win only when those tests prove real benefit.
Sources:
youtube.com, floridahealth.gov, flgov.com, x.com
